Full text is available at the source.
Abstract
Subcutaneous administration of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may hinder treatment adherence in patients with needle phobia.
- Needle phobia and agoraphobia are identified as significant barriers to adherence in obesity treatment.
- Oral alternatives to GLP-1 RAs are being evaluated as potential solutions to improve treatment adherence.
- The review focuses on the impact of psychological factors on the effectiveness of obesity pharmacotherapy.
Simplified